L. Dogliotti

发表

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

Sergio Ricci, S. Ricci, M. Moore, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Could the long-term persistence of low serum calcium levels and high serum parathyroid hormone levels during bisphosphonate treatment predispose metastatic breast cancer patients to undergo osteonecrosis of the jaw?

D. Generali, A. Bottini, L. Dogliotti, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC).

C. Boni, F. di Costanzo, M. Tonato, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer

M. Buyse, E. Dreher, Torri, 1998, The Lancet.

Pharmacoeconomic Comparison between Chronochemotherapy and Folfox Regimen in the Treatment of Patients with Metastatic Colorectal Cancer: A Cost-Minimization Study

M. Brizzi, L. Dogliotti, M. Tampellini, 2004, Tumori.

Hypoxia-Inducible Factor-1AExpression Predicts a Poor Response to Primary ChemoendocrineTherapy and Disease-Free Survival in Primary Human Breast Cancer

S. Fox, A. Harris, D. Generali, 2022 .

Randomized Comparison of Goserelin Acetate versus Mitomycin C plus Goserelin Acetate in Previously Untreated Prostate Cancer Patients with Bone Metastases

L. Dogliotti, O. Bertetto, D. Fontana, 1998, Tumori.

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients

S. Fox, A. Harris, D. Generali, 2010, Breast Cancer Research and Treatment.

Background to and Management of Treatment-Related Bone Loss in Prostate Cancer

L. Dogliotti, R. Scarpa, M. Tucci, 2002, Drugs & aging.

Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial.

F. Lévi, L. Dogliotti, C. Focan, 1994, Journal of the National Cancer Institute.

Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients.

L. Dogliotti, F. Bertoldo, M. Tucci, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potential clinical value of circulating chromogranin A in patients with prostate carcinoma.

L. Dogliotti, D. Fontana, E. Bollito, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Current Status of Hormonal Therapy of Fibrocystic Breast Disease a

L. Dogliotti, P. Fioretti, G. Melis, 1986, Annals of the New York Academy of Sciences.

Differences between temporal patterns of plasma cortisol and corticosteroid-binding globulin binding capacity throughout the twenty-four hour day and the menstrual cycle

L. Dogliotti, A. Angeli, F. Ceresa, 1978, Journal of endocrinological investigation.

1064 Gemcitabine-cisplatin combination in non-small cell lung cancer (NSCLC). A phase II study

L. Crinò, M. Marangolo, V. Adamo, 1995 .

Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial.

D. Amadori, L. Dogliotti, O. Bertetto, 2007, European urology.

A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5‐fluorouracil, and leucovorin as initial treatment of patients with metastatic colorectal carcinoma

F. Lévi, L. Dogliotti, C. Focan, 1999, Cancer.

Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer

F. di Costanzo, P. Bruzzi, L. Dogliotti, 2005, British Journal of Cancer.

Adjuvant sequential methotrexate → 5-fluorouracil vs 5-fluorouracil plus leucovorin in radically resected stage III and high-risk stage II colon cancer

P. Bruzzi, F. Costanzo, L. Dogliotti, 2004, British Journal of Cancer.

Six-year stabilisation of a relapsed pelvic mass from rectal cancer after oxaliplatin-containing chemotherapy

M. Papotti, L. Chiusa, M. Brizzi, 2007, Journal of Cancer Research and Clinical Oncology.

Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.

S. Cerutti, L. Dogliotti, D. Fontana, 2002, The Journal of urology.

The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen‐deprivation therapy

M. Papotti, L. Dogliotti, G. Ciccone, 2010, The Prostate.

Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease.

M. Papotti, S. Cappia, L. Dogliotti, 2007, The Journal of urology.

Changes in free and free-to-total prostate specific antigen after androgen deprivation or chemotherapy in patients with advanced prostate cancer.

L. Dogliotti, D. Fontana, A. Berruti, 1999, The Journal of urology.

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen

S. Fox, A. Harris, D. Generali, 2011, Breast Cancer Research.

Hormonal Treatment of Fibrocystic Disease

L. Dogliotti, P. Caraci, 1999 .

Categorization of Breast Cyst Fluid and Breast Cancer Risk

L. Dogliotti, P. Caraci, 1999 .

Low-dose monitored mitotane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer.

L. Dogliotti, E. Testa, A. Berruti, 2000, The Journal of clinical endocrinology and metabolism.

Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly.

L. Dogliotti, F. Porpiglia, F. Di Carlo, 2008, Endocrine-related cancer.

Comparison between Two Methods in the Determination of Circulating Chromogranin A in Neuroendocrine Tumors (NETs): Results of a Prospective Multicenter Observational Study

F. D. De Braud, R. Dittadi, M. Gion, 2005 .

Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors

F. D. De Braud, A. Scarpa, M. Falconi, 2011, Neuroendocrinology.

Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.

F. D. De Braud, G. delle Fave, M. Gion, 2007, Endocrine-related cancer.

Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease.

L. Dogliotti, F. Deltetto, M. Tampellini, 1997, British Journal of Cancer.

Immunomodulation of FOXP 3 + Regulatory TCells by theAromatase Inhibitor Letrozole in Breast Cancer Patients

S. Fox, A. Harris, A. Banham, 2009 .

Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Letrozole in Breast Cancer Patients

S. Fox, A. Harris, A. Banham, 2009, Clinical Cancer Research.

Thymidylate Synthase Expression in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors

G. Scagliotti, M. Papotti, P. Ceppi, 2008, Clinical Cancer Research.

Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma.

S. Cappia, L. Dogliotti, D. Fontana, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.

L. Dogliotti, E. Bollito, R. Scarpa, 2005, Endocrine-related cancer.

Co-expression of EGF receptor, TGFα and S6 kinase is significantly associated with colorectal carcinomas with distant metastases at diagnosis

M. Papotti, S. Cappia, L. Dogliotti, 2007, Virchows Archiv.

Zoledronic acid (Zometa ® ), a third generation bisphosphonate, for prevention of skeletal complications due to bone metastases.

L. Dogliotti, M. Tucci, A. Berruti, 2003 .

Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.

L. Dogliotti, D. Fontana, M. Tucci, 2001, The Journal of urology.

Paclitaxel, vinorelbine and 5-fluorouracil in breast cancer patients pretreated with adjuvant anthracyclines

D. Katsaros, D. Generali, V. Lorusso, 2005, British Journal of Cancer.

Hyperparathyroidism due to the so-called bone hunger syndrome in prostate cancer patients.

L. Dogliotti, R. Scarpa, M. Tucci, 2002, The Journal of clinical endocrinology and metabolism.

Transient increase in total serum alkaline phosphatase predicts radiological response to systemic therapy in breast cancer patients with osteolytic and mixed bone metastases.

L. Dogliotti, C. Raucci, A. Berruti, 1993, Oncology.

Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension.

L. Dogliotti, P. Paccotti, C. Raucci, 1996, British Journal of Cancer.

Serum Levels of Carboxyterminal Propeptide of Type I Procollagen in Cancer Patients with Osteoblastic and Osteolytic Bone Metastases

L. Dogliotti, C. Raucci, A. Berruti, 1994, The International journal of biological markers.

Serial evaluation of bone formation markers in breast cancer patients with bone metastases. Effect of chemotherapy with or without pamidronate

L. Dogliotti, C. Raucci, A. Berruti, 1995 .

Levels of eighteen non-conjugated and conjugated steroids in human breast cyst fluid: relationships with cyst type.

L. Dogliotti, F. Labrie, A. Bélanger, 1990, European journal of cancer.

Prognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease

L. Dogliotti, F. Porpiglia, G. Lamanna, 2009, Prostate Cancer and Prostatic Diseases.

The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.

D. Generali, A. Bottini, L. Dogliotti, 2007, Bone.

Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease

L. Dogliotti, F. Porpiglia, G. Lamanna, 2005, British Journal of Cancer.

Hypertriglyceridemia during Long-Term Interferon-Alpha Therapy: Efficacy of Diet and Gemfibrosil Treatment. A Case Report

L. Dogliotti, M. Tampellini, A. Berruti, 1992, Tumori.

Emerging drugs for adrenocortical carcinoma

M. Papotti, L. Dogliotti, A. Ferrero, 2008 .

Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma

L. Dogliotti, R. Scarpa, M. Tucci, 2002, Cancer.

Restless legs syndrome and its relationship with anxiety, depression, and quality of life in cancer patients undergoing chemotherapy

L. Ferini-Strambi, L. Ostacoli, R. Picci, 2010, Quality of Life Research.

Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer.

L. Dogliotti, A. Berruti, A. Angeli, 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.

A. Scarpa, M. Falconi, N. Fazio, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant mitotane treatment for adrenocortical carcinoma.

M. Papotti, P. Bruzzi, M. Fassnacht, 2007, The New England journal of medicine.

International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).

L. V. van't Veer, S. Fox, C. Sotiriou, 2011, Journal of the National Cancer Institute. Monographs.

European multicentre trial of bromocriptine in cyclical mastalgia

R. Mansel, L. Dogliotti, 1990, The Lancet.

Management of the side-effects of intravenous bisphosphonates: targeting the serum parathyroid hormone elevation.

D. Generali, L. Dogliotti, M. Tucci, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy.

L. Ostacoli, R. Picci, L. Dogliotti, 2013, Urologic oncology.

Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.

M. Moore, P. Conte, H. von der Maase, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

S. Ricci, M. Moore, L. Sengeløv, 2005 .

Prolactin and thyrotropin response to thyrotropin-releasing hormone in premenopausal women with fibrocystic disease of the breast.

L. Dogliotti, A. Angeli, F. Orlandi, 1985, Hormone research.

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

P. Albers, M. Moore, I. Bodrogi, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer.

L. Seymour, M. Moore, W. Stadler, 2002, Urologic oncology.

Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial.

L. Crinò, H. von der Maase, L. Dogliotti, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study.

G. Scagliotti, F. de Marinis, L. Crinò, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic factors in metastatic breast cancer patients obtaining objective response or disease stabilization after first-line chemotherapy with epirubicin. Evidence for a positive effect of maintenance hormonal therapy on overall survival.

P. Zola, A. Bottini, L. Dogliotti, 1997, Anticancer research.

Somatostatin receptors: from basic science to clinical approach. Unlabeled somatostatin analogues-1: Prostate cancer.

S. Lamberts, L. Dogliotti, L. Hofland, 2004, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Comparison between two methods in the determination of circulating chromogranin A in neuroendocrine tumors (NETs): results of a prospective multicenter observational study.

F. D. De Braud, G. delle Fave, R. Dittadi, 2005, The International journal of biological markers.

Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen.

M. Papotti, L. Dogliotti, M. Motta, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Serum and urinary profile of bone turn-over markers in a patient with tamoxifen-induced hypercalcaemia submitted to pamidronate therapy

L. Dogliotti, A. Berruti, A. Piovesan, 1996 .

Estroe‐3‐Sulfate in Human Breast Cyst Fluid a

L. Dogliotti, A. Angeli, F. Orlandi, 1990 .

Estrone-3-sulfate in human breast cyst fluid. Relationship to cation-related cyst subpopulations.

L. Dogliotti, A. Angeli, F. Orlandi, 1990, Annals of the New York Academy of Sciences.

Apocrine cells in breast cyst fluid and their relationship to cyst type: a morphometric study.

L. Dogliotti, D. Beccati, C. Naldoni, 1988, European journal of cancer & clinical oncology.

Criteria for Classifying Breast Cyst Fluids

C. Bodian, L. Dogliotti, D. Haagensen, 1990, Annals of the New York Academy of Sciences.

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases

A. Harris, D. Generali, A. Bottini, 2008, British Journal of Cancer.

Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon‐alpha‐2a: A study by the Italian trials in Medical Oncology Group

R. Labianca, L. Mariani, S. Pilotti, 1993, Cancer.

Effect of zoledronic acid (Z) treatment based on serum parathyroid hormone (PTH) levels in patients (pts) with malignant bone disease.

F. Saad, L. Dogliotti, R. Cook, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis

D. Generali, A. Bottini, L. Dogliotti, 2007, Osteoporosis International.

Increased antiresorptive activity of zoledronic acid (Z) administered in the night as compared to morning administration in breast cancer (BC) patients with bone metastases.

D. Generali, A. Bottini, L. Dogliotti, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Modulation of cytotoxic drug activity by mitotane and lonidamine in human adrenocortical carcinoma cells.

N. Zaffaroni, L. Orlandi, R. Villa, 1999, International journal of oncology.

The endocrine basis of benign breast disorders

L. Dogliotti, A. Angeli, F. Orlandi, 1989, World Journal of Surgery.

Phase II trial of continuous/metronomic 5-fluorouracil infusion plus long acting Octreotide in advanced neuroendocrine carcinoma

M. Brizzi, L. Dogliotti, L. Ciuffreda, 2007 .

Pamidronate administration improves the secondary hyperparathyroidism due to “Bone hunger syndrome” in a patient with osteoblastic metastases from prostate cancer

L. Dogliotti, A. Berruti, A. Angeli, 1997, The Prostate.

Thyroid hormone levels in human breast cyst fluid.

L. Dogliotti, A. Angeli, R. Cavallo, 1984, Acta endocrinologica.

Correlation between Levels of Dehydroepiandrosterone-Sulphate and Prolactin in Human Breast Cyst Fluid

L. Dogliotti, E. Brignardello, G. Boccuzzi, 1982, Tumori.

[Antiprolactin therapy in the treatment of benign lesions of the breast. Comparison of bromocryptine and methergoline].

L. Dogliotti, S. Sandrucci, A. Mussa, 1979, Minerva medica.

Treatment of benign breast disease with bromocriptine

L. Dogliotti, A. Mussa, 1979, Journal of endocrinological investigation.

Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P).

S. Cerutti, L. Dogliotti, O. Bertetto, 1997, Anticancer research.

The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy.

L. Dogliotti, M. Tampellini, G. Gorzegno, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Acute Myeloblastic Leukemia Associated with Mediastinal Nonseminomatous Germ Cell Tumors. Report on two Cases

L. Dogliotti, A. Berruti, G. Gorzegno, 1995, Tumori.

Long-term disease free survival in a patient with metastatic adreno-cortical carcinoma after complete pathological response to chemotherapy plus mitotane

L. Dogliotti, P. Paccotti, F. Porpiglia, 2006, Journal of endocrinological investigation.

Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.

L. Dogliotti, R. Scarpa, M. Tucci, 2003, Journal of the National Cancer Institute.

Could the efficacy of docetaxel in prostate cancer patients be potentiated by concomitant high-dose calcitriol administration?

L. Dogliotti, M. Tucci, A. Berruti, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mediastinal non-seminomatous germ cell tumours: effectiveness of platinum, etoposide, bleomycin combination chemotherapy plus adjunctive surgery.

L. Dogliotti, P. Borasio, A. Berruti, 1992, European journal of cancer.

Prolactin Dynamics after Acute Stimulation with Thyrotropin‐Releasing Hormone and Domperidone in Women with Fibrocystic Disease of the Breast

L. Dogliotti, A. Angeli, F. Orlandi, 1986 .

Meta-analysis of randomized trials comparing cisplatin versus carboplatin-based regimens for the first-line therapy of metastatic transitional cell carcinoma of the urothelium (TCCU).

G. Sonpavde, W. Oh, M. Galsky, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevention of Nausea and Vomiting in Cisplatin-Treated Patients by a Selective 5-Hydroxytryptamine (5-HT3) Receptor Antagonist, ICS 205-930

L. Dogliotti, A. Berruti, C. Ortega, 1990, Tumori.

Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.

L. Dogliotti, M. Tampellini, A. Berruti, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Stage IB Malignant Thymoma in a Lynch Syndrome Patient with Multiple Cancers: Response to Incidental Administration of Oxaliplatin and 5-Fluorouracil

D. Giachino, L. Dogliotti, M. Barberis, 2006, Journal of chemotherapy.

Multimodal management of stages III-IVa malignant thymoma.

L. Dogliotti, F. Ardissone, Sannazzari Gl, 2004, Lung cancer.

Shifted distribution of cation-related cyst types in post-menopausal patients with gross cystic disease of the breast.

L. Dogliotti, C. Naldoni, A. Angeli, 1987, Maturitas.

Risk of depressive events in long-term surviving patients affected by hormone-related cancer according to time after diagnosis.

L. Ostacoli, R. Picci, L. Dogliotti, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatment.

S. Cerutti, L. Dogliotti, A. Berruti, 2000, Oncology reports.

[Male breast carcinoma. Review of the literature and report of cases].

L. Dogliotti, A. Mussa, G. Sacchetto, 1982, Minerva chirurgica.

Favorable Response of Metastatic Adrenocortical Carcinoma to Etoposide, Adriamycin and Cisplatin (EAP) Chemotherapy. Report of two Cases

L. Dogliotti, F. Veglio, P. Paccotti, 1992, Tumori.

Emerging drugs for adrenocortical carcinoma.

M. Papotti, L. Dogliotti, A. Ferrero, 2008, Expert opinion on emerging drugs.

Relationship to Cation-Related Cyst Sub populations

L. Dogliotti, F. Orlandi, B. Puligheddu, 2006 .

Prevalence of adrenal incidentaloma in a contemporary computerized tomography series

G. Scagliotti, S. Novello, L. Dogliotti, 2006, Journal of endocrinological investigation.

Comparison between two commercially available chromogranin A assays in detecting neuroendocrine differentiation in prostate cancer and benign prostate hyperplasia.

Dario Fontana, Alessandra Mosca, Giuseppe Aimo, 2007, Clinica chimica acta; international journal of clinical chemistry.

Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy

M. Papotti, A. Colao, A. Faggiano, 2007, Modern Pathology.

Melatonin and human cancer

A. Bottini, L. Dogliotti, M. Tampellini, 1990, The Journal of Steroid Biochemistry and Molecular Biology.

Melatonin relationship to human tumors

L. Dogliotti, A. Berruti, M. Terzolo, 1987 .

Comparison of Assay of Total and Bone-Specific Alkaline Phosphatase in the Assessment of Osteoblast Activity in Patients with Metastatic Bone Disease

L. Dogliotti, A. Berruti, A. Piovesan, 1997, Calcified Tissue International.

The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients

M. Aglietta, M. Brizzi, L. Dogliotti, 2006, British Journal of Cancer.

The role of hemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer (ACC) patients

M. Brizzi, L. Dogliotti, M. Tampellini, 2004 .

Hypoxia-Inducible Factor-1α Expression Predicts a Poor Response to Primary Chemoendocrine Therapy and Disease-Free Survival in Primary Human Breast Cancer

Manuela Milani, Stephen B. Fox, Adrian L. Harris, 2006, Clinical Cancer Research.

Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.

Manuela Milani, Stephen B Fox, Adrian L Harris, 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast

P. Bruzzi, L. Dogliotti, C. Naldoni, 1997, BMJ.

Steroid biochemistry and categorization of breast cyst fluid: relation to breast cancer risk

P. Bruzzi, L. Dogliotti, C. Naldoni, 1994, The Journal of Steroid Biochemistry and Molecular Biology.

Association of cyst type with risk factors for breast cancer and relapse rate in women with gross cystic disease of the breast.

M. Costantini, P. Bruzzi, L. Dogliotti, 1992, Cancer research.

Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer

P. Bruzzi, D. Generali, M. Brizzi, 2001, British Journal of Cancer.

Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.

L. Dogliotti, D. Fontana, F. Porpiglia, 2000, The Journal of urology.

Down-Regulation of Phosphatidylinositol 3′-Kinase/AKT/Molecular Target of Rapamycin Metabolic Pathway by Primary Letrozole-Based Therapy in Human Breast Cancer

S. Fox, A. Harris, D. Generali, 2008, Clinical Cancer Research.

Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience

M. Brizzi, L. Dogliotti, F. Ardissone, 1999, British Journal of Cancer.

Biochemistry of Breast Cyst Fluid a

L. Dogliotti, A. Angeli, F. Orlandi, 1990, Annals of the New York Academy of Sciences.

Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.

S. Fox, A. Harris, P. Bruzzi, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

G. Sonpavde, W. Oh, M. Galsky, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

G. Sonpavde, W. Oh, M. Galsky, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.

P. Casali, L. Dogliotti, F. Porpiglia, 2005, Endocrine-related cancer.

Endocrinology of the breast: basic and clinical aspects. Turin, Italy, September 19-22, 1984.

L. Dogliotti, H. Bradlow, A. Angeli, 1986, Annals of the New York Academy of Sciences.

Randomized phase II study of danusertib in patients with metastatic castration‐resistant prostate cancer after docetaxel failure

F. Cappuzzo, C. Sternberg, E. Raymond, 2013, BJU international.

Circulating neuroendocrine markers in patients with prostate carcinoma

L. Dogliotti, D. Fontana, E. Bollito, 2000, Cancer.

Multicenter Phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small cell lung cancer patients.

L. Dogliotti, D. Perroni, G. Grecchi, 1996, Lung cancer.

Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease.

L. Dogliotti, M. Tampellini, A. Berruti, 1994, European journal of cancer.

Regulation of Hepatocyte Growth Factor Activator Inhibitor 2 by Hypoxia in Breast Cancer

S. Fox, A. Harris, D. Generali, 2007, Clinical Cancer Research.

Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer

D. Generali, M. Brizzi, A. Bottini, 2003, British Journal of Cancer.

Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer.

D. Generali, M. Brizzi, A. Bottini, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.

M. Brizzi, A. Bottini, L. Dogliotti, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.

S. Fox, A. Harris, D. Generali, 2011, Journal of the National Cancer Institute. Monographs.

Medroxyprogesterone acetate high dose mpa hd versus mpa hd plus bromocriptine in advanced breast cancer preliminary results of a multicenter randomized clinical trial

L. Dogliotti, G. R. Cuna, 1987 .

Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours.

M. Brizzi, A. Bottini, L. Dogliotti, 1996, Anticancer research.

Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions.

P. Bruzzi, D. Generali, M. Brizzi, 2008, The oncologist.

Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle

L. Dogliotti, F. Vignani, V. Bertaglia, 2010, Open access journal of urology.

International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

S. Fox, M. Dowsett, A. Harris, 2011, Journal of the National Cancer Institute. Monographs.

Gene expression profiling in breast cancer: a clinical perspective.

Fabio Puglisi, Anna Sapino, A. Sapino, 2013, Breast.

The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.

L. Dogliotti, A. Berruti, A. Mosca, 2005, Journal of endocrinological investigation.

Prognostic significance of prolactin receptor on overall survival of patients with early breast cancer: a long-term retrospective analysis

L. Dogliotti, C. Ortega, G. Muccioli, 1994 .

Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic review.

L. Dogliotti, G. Ciccone, C. Buttigliero, 2011, The oncologist.

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.

M. Papotti, A. Priola, C. Intrivici, 2010, Endocrine-related cancer.

Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma

L. Dogliotti, A. Berruti, M. Terzolo, 1998, Cancer.

Mammary cysts: pathophysiology and biochemistry.

L. Dogliotti, D. Beccati, A. Angeli, 1987, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

Vinorelbine as second line treatment in anthracycline pre-treated advanced breast cancer patients: A phase II study

L. Dogliotti, G. Gorzegno, A. Farris, 1993 .

Feasibility of the association of mitotane with etoposide, adriamycin and cisplatin combination chemotherapy in advanced adrenocortical cancer patients. Report on 7 cases.

L. Dogliotti, P. Paccotti, C. Letizia, 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.

S. Fox, A. Harris, M. Papotti, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Independent Factors Predict Supranormal CA 15-3 Serum Levels in Advanced Breast Cancer Patients at First Disease Relapse

P. Arese, A. Bottini, L. Dogliotti, 2001, Tumor Biology.

Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience.

L. Dogliotti, M. Tampellini, A. Berruti, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study

P. Zola, A. Bottini, L. Dogliotti, 1998, Cancer Chemotherapy and Pharmacology.

Influence of neoadjuvant chemotherapy on serum tumor markers CA 15-3, MCA, CEA, TPS and TPA in breast cancer patients with operable disease.

M. Brizzi, A. Bottini, L. Dogliotti, 1997, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Diagnosis, Management and Clinical Outcome of Bone Metastases in Breast Cancer Patients: Results from a Prospective, Multicenter Study

S. Barni, R. Labianca, V. Torri, 2007, Oncology.

Combination regimen of epirubicin, vinorelbine and 5-fluorouracil continuous infusion as first-line chemotherapy in anthracycline-naive metastatic breast cancer patients.

D. Katsaros, A. Bottini, L. Dogliotti, 2005, European Journal of Cancer.

Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers.

G Cortese, C Fava, G. Scagliotti, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.

J. Moul, C. Sternberg, V. Guillem, 2008, Critical reviews in oncology/hematology.

Magnetic Resonance Imaging in Comparison to Clinical Palpation in Assessing the Response of Breast Cancer to Epirubicin Primary Chemotherapy

D. Generali, M. Brizzi, A. Bottini, 2004, Breast Cancer Research and Treatment.

Accuracy of mammography and echography versus clinical palpation in the assessment of response to primary chemotherapy in breast cancer patients with operable disease

M. Brizzi, A. Bottini, L. Dogliotti, 2001, Breast Cancer Research and Treatment.

Combination Chemotherapy with Carboplatin and Methotrexate in the Treatment of Advanced Urothelial Carcinoma: A Phase II Study

L. Fanchini, L. Dogliotti, O. Bertetto, 1995, American Journal of Clinical Oncology.

Biochemistry of breast cyst fluid: correlation with breast cancer risk.

L. Dogliotti, A. Angeli, F. Chasalow, 1990, Annals of the New York Academy of Sciences.

Gemcitabine and protracted 5-fluorouracil infusion as third-line chemotherapy in refractory colorectal cancer patients.

M. Brizzi, L. Dogliotti, A. Ferrero, 2008, Anticancer research.

Effects of the somatostatin analog lanreotide on the circulating levels of chromogranin‐A, prostate‐specific antigen, and insulin‐like growth factor‐1 in advanced prostate cancer patients

L. Dogliotti, A. Berruti, A. Mosca, 2001, The Prostate.

Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.

S. Fox, A. Harris, P. Bruzzi, 2006, Endocrine-related cancer.

Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial.

D. Generali, M. Brizzi, A. Bottini, 2005, Endocrine-related cancer.

Management of neuroendocrine differentiated breast carcinoma.

S. Cappia, L. Dogliotti, P. Borasio, 2004, Breast.

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the xelbevoct study

M. Papotti, A. Priola, N. Fazio, 2014, BMC Cancer.

Phase II study of vinorelbine with protracted fluorouracil infusion as a second- or third-line approach for advanced breast cancer patients previously treated with anthracyclines.

V. Lorusso, A. Bottini, M. de Lena, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design.

P. Bruzzi, V. Lorusso, A. Bottini, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biochemical picture of bone metabolism in breast cancer patients with bone metastases.

L. Dogliotti, C. Raucci, A. Berruti, 1995, Anticancer research.

Laboratory tests for neuroendocrine tumours.

L. Dogliotti, E. Seregni, L. Ferrari, 2000, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases.

S. Cerutti, L. Dogliotti, M. Tampellini, 1999, Clinical chemistry.

Intermediate endpoints of primary systemic therapy in breast cancer patients.

P. Bruzzi, D. Generali, M. Brizzi, 2011, Journal of the National Cancer Institute. Monographs.

Feasibility of 21-day continuous infusion of epirubicin in hormone-refractory prostate cancer patients.

L. Dogliotti, F. Porpiglia, R. Scarpa, 2005, Anticancer research.

Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial.

P. Zola, A. Bottini, L. Dogliotti, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte Oncology Network

M. Papotti, M. Brizzi, L. Dogliotti, 2009, BMC Cancer.

Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients

A. Bottini, L. Dogliotti, M. Massobrio, 2006, Breast Cancer Research and Treatment.

Reversible pancytopenia caused by oral letrozole assumption in a patient with recurrent breast cancer.

L. Dogliotti, A. Berruti, G. Gorzegno, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

La Cronochemioterapia

L. Dogliotti, C. Garufi, Stefano Iacobelli, 2000 .

p53 expression and disease outcome of breast cancer patients undergoing primary chemotherapy with anthracycline-containing regimens.

M. Brizzi, A. Bottini, L. Dogliotti, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Wolfe's mammographic patterns in women with gross cystic disease of the breast.

M. Costantini, P. Bruzzi, L. Dogliotti, 1995, Journal of clinical epidemiology.

Cations and dehydroepiandrosterone-sulfate in cyst fluid of pre- and menopausal patients with gross cystic disease of the breast. Evidence for the existence of subpopulations of cysts.

L. Dogliotti, C. Naldoni, A. Angeli, 1986, European journal of cancer & clinical oncology.

Neoadjuvant chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide (ADOC) in invasive thymomas: results in six patients.

L. Dogliotti, P. Borasio, A. Berruti, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Objective response to epirubicin and lonidamine. A case of advanced thymoma previously treated with the ADOC scheme and unresponsive to paclitaxel plus cyclophosphamide.

L. Dogliotti, M. Tampellini, A. Berruti, 1997, Chest.

UROLOGICAL ONCOLOGY: BLADDER, PENIS AND URETHRA CANCER, AND BASIC PRINCIPLES OF ONCOLOGY Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

S. Ricci, M. Moore, L. Sengeløv, 2006 .

Cytotoxic chemotherapy for adrenocortical carcinoma.

L. Dogliotti, P. Paccotti, A. Berruti, 1995, Minerva endocrinologica.

Is pathologic complete response a valid surrogate parameter of treatment efficacy in HER2 positive breast cancer patients undergoing primary chemotherapy plus trastuzamab?

D. Generali, M. Brizzi, A. Bottini, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p 53 but not bcl-2 Immunostaining Is Predictive of Poor Clinical Complete Response to Primary Chemotherapy in Breast Cancer Patients 1

M. Brizzi, A. Bottini, L. Dogliotti, 2000 .

Lack of Activity of Docetaxel in Soft Tissue Sarcomas: Results of a Phase II Study of the Italian Group on Rare Tumors

P. Bruzzi, A. Santoro, L. Dogliotti, 1999, Sarcoma.

Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases.

L. Dogliotti, R. Scarpa, M. Tampellini, 2002, The International journal of biological markers.

Metabolic Effects of Single-Dose Pamidronate Administration in Prostate Cancer Patients with Bone Metastases

L. Dogliotti, R. Scarpa, M. Tampellini, 2002 .

Irinotecan and chronomodulated infusion of 5‐fluorouracil and folinic acid in the treatment of patients with advanced colorectal carcinoma

L. Dogliotti, R. D'Attino, M. Tampellini, 2001, Cancer.

Cytotoxic and antiproliferative activity of the CMF regimen administered in association with tamoxifen as primary chemotherapy in breast cancer patients.

M. Brizzi, A. Bottini, L. Dogliotti, 1998, International journal of oncology.

Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC).

G. Scagliotti, C. Gridelli, S. Novello, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prevalence of complementary/alternative medicines (CAMs) in a cancer population in northern Italy receiving antineoplastic treatments and relationship with quality of life and psychometric features

L. Ostacoli, R. Picci, L. Dogliotti, 2011, Quality of Life Research.

Prognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle

L. Dogliotti, F. Vignani, V. Bertaglia, 2010, Open Access Journal of Urology.

Is an Antiemetic Prophylactic Treatment Needed for Patients Submitted to Consecutive Days of 5-fluorouracil? An Observational Study

A. Favero, M. Maltoni, D. Amadori, 2001, Tumori.

I. Bodrogi, P. Conte, L. Dogliotti, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Oral estramustine plus oral etoposide in the treatment of hormone refractory prostate cancer patients: a phase II study with a 5-year follow-up.

L. Dogliotti, O. Bertetto, D. Fontana, 2005, Urologic oncology.

P-268 Three-year findings of an early lung cancer detection feasibilitystudy with low-dose spiral computed tomography in heavy smokers

G. Scagliotti, L. Dogliotti, C. Fava, 2005 .

Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation.

L. Dogliotti, M. Tampellini, A. Berruti, 2006, The Lancet. Oncology.

Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study.

I. Bodrogi, P. Conte, H. von der Maase, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durable complete remission after weekly docetaxel administration in a patient with mediastinal non-seminomatous germ-cell tumor refractory to cisplatin-based chemotherapy.

L. Dogliotti, P. Borasio, M. Tampellini, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic review.

L. Dogliotti, G. Ciccone, C. Buttigliero, 2011, The oncologist.

Gene expression profiling in breast cancer: a clinical perspective.

A. Sapino, F. Puglisi, G. Arpino, 2013, Breast.

Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach.

J. Moul, C. Sternberg, V. Guillem, 2008, Critical reviews in oncology/hematology.

Combined Epirubicin and Interleukin-2 Regimen in the Treatment of Malignant Mesothelioma: A Multicenter Phase II Study of the Italian Group on Rare Tumors

P. Bruzzi, A. Santoro, L. Dogliotti, 1998, Tumori.

Three Years’ Experience with Tropisetron in the Control of Nausea and Vomiting in Cisplatin-Treated Patients

L. Dogliotti, A. Berruti, C. Ortega, 2012, Drugs.

Low dose CT in early lung cancer diagnosis: Prevalence data.

Cesare Fava, G. Scagliotti, S. Novello, 2005, La Radiologia medica.

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.

M. Papotti, A. Priola, C. Intrivici, 2010, Endocrine-related cancer.